Epidemiology and Outcomes of Hospitalizations for Children with Encephalopathy Associated with Severe Liver

Lilia Christner1, Achamyeleh Gebremariam1,2, Folafoluwa Odetola1,2,3

  • 1Department of Pediatrics, University of Michigan, Ann Arbor, MI.

Insights

Nearly half of children hospitalized for severe liver dysfunction-associated encephalopathy die. Patient factors like comorbidities and multiple organ dysfunction (MOD) impact mortality, not hospital characteristics. Individualized, age-specific care is crucial.

Area of Science:

  • Pediatric critical care medicine
  • Hepatology
  • Public health

Background:

  • Severe liver dysfunction-associated encephalopathy (SLD-AE) poses a significant mortality risk in children.
  • Understanding patient- and hospital-level factors is crucial for improving outcomes.

Purpose of the Study:

  • To identify independent patient- and hospital-level factors associated with mortality in pediatric SLD-AE.

Main Methods:

  • Retrospective analysis of US hospitalizations (2016, 2019, 2022) using the Kids' Inpatient Database.
  • Multivariable logistic regression models were used to assess mortality predictors.

Main Results:

  • Of 3378 hospitalizations, 45% resulted in in-hospital mortality.
  • Mortality was associated with patient factors: age, multiple organ dysfunction (MOD), and comorbidities.
  • No significant association was found between mortality and hospital characteristics.

Conclusions:

  • High mortality (45%) in pediatric SLD-AE highlights an urgent need for intervention.
  • Individualized, age-specific management strategies focusing on MOD and comorbidities are essential.
  • No regional or hospital-level variations in mortality were observed.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
249
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
315
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
329
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
735
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
331
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
283